The E3 ubiquitin ligase MARCH5 promotes mitochondrial fusion and cell-cycle progression in acute myeloid leukemia

Acute myeloid leukemia (AML) is a rapidly progressing blood cancer characterized by excessive growth of transformed immature progenitor cells in the bone marrow and bloodstream. 1,2 Although chemotherapy is the primary treatment modality for AML, its efficacy is often compromised by the emergence of drug-resistant cells, leading to disease relapse and poor patient outcomes.This highlights the urgent need for innovative therapeutic approaches. 2 Recently, the B-cell lymphoma 2 inhibitor venetoclax has shown great promise in AML therapy.By targeting mitochondrial antiapoptotic pathways, venetoclax has improved survival in combination with cytarabine or 5-azacytidine, establishing these combinations as the new standard of care for patients ineligible for intensive chemotherapy. 3,4The potent antileukemic activity of venetoclax underscores the importance of mitochondria as a central target in the development of novel AML therapies.In particular, mitochondrial metabolism is a critical vulnerability of leukemic stem cells (LSCs), a rare cell subset responsible for driving drug resistance and relapse in AML. [5][6]6][7][8][9] LSCs also rely heavily on mitophagy, a specialized form of autophagy that facilitates the removal of damaged mitochondria to maintain cell survival. 10,11Our recent investigations into mitochondrial vulnerability in AML have shown that disruption of mitochondrial fusion by silencing mitofusin 2 (MFN2) or optic atrophy 1 (OPA1) leads to cell-cycle arrest and significant antileukemic effects both in vitro and in vivo. 12However, the detailed mechanisms by which mitochondrial dynamics influence cell-cycle transitions remain largely unexplored.To address this gap, we performed a comprehensive analysis of mitochondrial morphology and dynamics in quiescent and cycling cells using patient-derived xenograft (PDX) models of AML in immunodeficient NOD/SCID/IL-2R-chain null (NSG) mice (Figure 1A; supplemental Table 1).In PDX-AML samples containing 89% to 98% human AML cells, confocal imaging revealed significantly larger mitochondria in cycling (Ki-67 + ) cells than quiescent (Ki-67 -) cells (Figure 1B; supplemental Figure1A; supplemental Table 1).To investigate the differential requirements of key mitochondrial membrane dynamics factors during cell-cycle progression, we sorted quiescent and cycling leukemic cells and performed targeted gene and protein expression analyses in these populations (Figure 1C).The factors analyzed included profusion (MFN1, MFN2, and OPA1) and profission (mitochondrial fission factor and dynamin-like 1) proteins, as well as the mitochondrial E3 ubiquitin ligase membrane-associated ring-CH-type finger 5 (MARCH5), which posttranslationally regulates several of these mitochondrial dynamics factors. [13][14]4][15][16][17] Notably, MARCH5 was the most differentially overexpressed in cycling compared with quiescent PDX-AML cells (Figure 1D-E; supplemental Table 2).To identify MARCH5 targets in AML cells, we performed interactome profiling by immunoprecipitation.We expressed wild-type MARCH5 and an E3-ligase-deficient mutant form of MARCH5 (MARCH5-H43W) in the OCI-AML2 AML cell line (supplemental Figure 1B). 16Quantitative proteomics on the immunoprecipitation products identified several binding partners of MARCH5, including MFN2, whose interaction was dependent on the E3-ligase activity of MARCH5 (Figure 1F-G).However, MARCH5 knockdown did not alter MFN1 or MFN2 protein expression in the MOLM-14 and

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.